LoopLab Bio

Ownership

Private

Employees

~24

Therapeutic Areas

OncologyImmunologyNeurologyInfectious Diseases

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Self-Amplifying Biologics (SelfAmps)novel virus-based therapeutics

LoopLab Bio General Information

LoopLab Bio develops a new class of virus-based therapeutics called Self-Amplifying Biologics (“SelfAmps”), designed for targeted treatment of immunological and potentially other serious diseases. The technology involves engineering viral backbones for cell/tissue specificity, delivering disease-relevant payloads with immune modulation. As of early 2024/2025, the company appears to be in preclinical development with no disclosed clinical results or programs yet in human trials.

Contact Information

Website

https://www.looplab.bio/imprint-privacy-policy

Primary Industry

Biotech

Corporate Office

Vienna, Vienna
Austria

Drug Pipeline

No pipeline data available

For full access to LoopLab Bio's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

LoopLab Bio Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view LoopLab Bio's complete valuation and funding history, request access »